Drug Profile
Research programme: Alzheimer's disease therapeutic - Bioiberica
Alternative Names: PRJ 212Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Bioiberica
- Class Antidementias
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Alzheimer's disease in Spain (PO) (Bioiberica pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Alzheimer's-disease in Spain (PO)
- 29 Nov 2016 Bioiberica plans a clinical trial for Alzheimer's disease in Spain (NCT02991235)